Nakahama H, Miwa Y, Yamaji A, Orita Y, Fukuhara Y, Yanase M, Kamada T, Sonoda T, Ishibasi M, Ichikawa Y
Eur J Clin Pharmacol. 1987;32(3):313-5. doi: 10.1007/BF00607581.
Urine from 5 renal transplant recipients treated with frusemide was analyzed for unchanged frusemide (F), glucuronidated frusemide (G) and 4-chloro-5-sulfamoylanthranilic acid (CSA) by HPLC. In 3 recipients, whose renal function recovered steadily and whose hepatic function was normal throughout, the ratio of frusemide to its metabolites, F/(F + G + CSA), increased steadily in conjunction with the recovery of renal function. In one patient, who received frusemide 200-400 mg/day i.v., the urinary CSA concentration was 64-102 micrograms X ml-1. In 2 patients who experienced shock and/or hepatic dysfunction after transplantation, the F/(F + G + CSA) ratio fluctuated.
通过高效液相色谱法（HPLC）分析了5例接受速尿治疗的肾移植受者尿液中的未代谢速尿（F）、速尿葡萄糖醛酸化物（G）和4-氯-5-氨磺酰基邻氨基苯甲酸（CSA）。在3例肾功能稳步恢复且肝功能始终正常的受者中，速尿与其代谢物的比例F/（F+G+CSA）随着肾功能的恢复而稳步增加。在1例静脉注射速尿200 - 400mg/天的患者中，尿中CSA浓度为64 - 102微克×毫升⁻¹。在2例移植后出现休克和/或肝功能障碍的患者中，F/（F+G+CSA）比例波动。
